<?xml version="1.0" encoding="UTF-8"?>
<document id="28602620">
	<sentence id="s1" text="We identified integrin a7 (heterotypic cell-cell adhesion) as a major laminin receptor in GSCs and in primary high-grade glioma specimens.">
		<entity id="s1.e1" charOffset="27-57"
			type="GO" text="heterotypic cell-cell adhesion" ontology_id="GO_0034113"/>
		<entity id="s1.e2" charOffset="121-127"
			type="HP" text="glioma" ontology_id="HP_0009733"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
	</sentence>
	<sentence id="s2" text="Analyses of mRNA profiles in comprehensive datasets revealed that high heterotypic cell-cell adhesion expression negatively correlated with survival of patients with both low- and high-grade glioma.">
		<entity id="s2.e1" charOffset="71-101"
			type="GO" text="heterotypic cell-cell adhesion" ontology_id="GO_0034113"/>
		<entity id="s2.e2" charOffset="191-197"
			type="HP" text="glioma" ontology_id="HP_0009733"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
	</sentence>
	<sentence id="s3" text="We also found that targeting of heterotypic cell-cell adhesion by RNAi or blocking mAbs impaired laminin-induced signaling, and it led to a significant delay in tumor engraftment plus a strong reduction in tumor size and invasion.">
		<entity id="s3.e1" charOffset="32-62"
			type="GO" text="heterotypic cell-cell adhesion" ontology_id="GO_0034113"/>
		<entity id="s3.e2" charOffset="161-166"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
	</sentence>
	<sentence id="s4" text="Our data, therefore, highlight heterotypic cell-cell adhesion as a glioblastoma biomarker and candidate therapeutic target">
		<entity id="s4.e1" charOffset="31-61"
			type="GO" text="heterotypic cell-cell adhesion" ontology_id="GO_0034113"/>
		<entity id="s4.e2" charOffset="67-79"
			type="HP" text="glioblastoma" ontology_id="HP_0012174"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e2" pgr="false"/>
	</sentence>
</document>
